Results 221 to 230 of about 9,201,564 (391)

Mathematical Modeling of Neuroinflammation in Neurodegenerative Diseases

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Age‐related neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD) are an increasing public health concern. Whereas the pathology of these diseases is complex, chronic central inflammation, or neuroinflammation, is commonly observed across many neurodegenerative diseases ...
Alex Foster‐Powell, Amin Rostami‐Hodjegan, Guy Meno‐Tetang, Donald E. Mager, Kayode Ogungbenro   +4 more
wiley   +1 more source

Long-term outcome of presymptomatic testing in Huntington disease [PDF]

, 2008
Marcela Gargiulo, Séverine Lejeune, Marie‐Laure Tanguy, Khadija Lahlou‐Laforêt, Anne Faudet, David Cohen, Josué Feingold, Alexandra Dürr   +7 more
openalex   +1 more source

Huntington's disease: a clinical review

European Journal of Neurology, 2018
P. McColgan, S. Tabrizi
semanticscholar   +1 more source

Modeling Disease Progression and Placebo Response in Huntington Disease: Insights From Enroll-HD and GENERATION HD1 Cohorts. [PDF]

Neurology
Boareto M, Yamamoto Y, Long JD, Sampaio C, McColgan P, Diack C, Ducray PS.   +6 more
europepmc   +1 more source

Criminality in Huntington Disease. [PDF]

Neurol Clin Pract, 2022
Olvera C, Stebbins GT, Romero VP, Hall DA.   +3 more
europepmc   +1 more source

Sex-dependent Effect of BAG1 in Ameliorating Motor Deficits of Huntington Disease Transgenic Mice [PDF]

, 2008
Adam L. Orr, Shanshan Huang, Meredith Roberts, John C. Reed, Shihua Li, Xiaojiang Li   +5 more
openalex   +1 more source

Integrated Modeling of Digital‐Motor and Clinician‐Reported Outcomes Using Item Response Theory: Towards Powerful Trials for Rare Neurological Diseases

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Robust and highly sensitive outcomes are crucial for small trials in rare diseases. Combining different outcome types might improve sensitivity to identify disease severity and progression, yet innovative methodologies are scarce. Here we develop an Item Response Theory framework that allows integrated modeling of both continuous and ...
Alzahra Hamdan, Andreas Traschütz, Lukas Beichert, Xiaomei Chen, Cynthia Gagnon, Bart P. van de Warrenburg, Filippo M. Santorelli, Nazlı Başak, Giulia Coarelli, Rita Horvath, Stephan Klebe, PROSPAX consortium, EVIDENCE‐RND consortium, Rebecca Schüle, Andrew C. Hooker, Matthis Synofzik, Mats O. Karlsson   +16 more
wiley   +1 more source

Vitamin C Transport Deficiency Alters Striatal Dopamine Gene Expression and Metabolism in YAC128 Huntington Disease Mice. [PDF]

Genes Brain Behav
Tienda AA, Harrison FE, Wilcox JM.
europepmc   +1 more source

A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease. [PDF]

Bioinform Biol Insights, 2023
Meem TM, Khan U, Mredul MBR, Awal MA, Rahman MH, Khan MS.   +5 more
europepmc   +1 more source

Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The GenePD study [PDF]

, 2008
Christopher F. McNicoll, Jeanne C. Latourelle, Marcy E. MacDonald, Mark Lew, Oksana Suchowersky, Christine Klein, Lawrence I. Golbe, Margery H. Mark, John H. Growdon, G. Frederick Wooten, Ray L. Watts, Mark Guttman, Brad A. Racette, Joel S. Perlmutter, Anwar Ahmed, Holly A. Shill, Carlos Singer, Marie Saint‐Hilaire, Tiffany Massood, Karen W. Huskey, Anita L. DeStefano, Tammy Gillis, Jayalakshmi Srinidhi Mysore, Stefano Goldwurm, Gianni Pezzoli, Kenneth B. Baker, Ilia Itin, Irene Litvan, Garth A. Nicholson, Alastair Corbett, Martha Nance, Edward Drasby, Stuart Isaacson, David J. Burn, Patrick F. Chinnery, Peter P. Pramstaller, Jomana T. Al‐Hinti, Anette Torvin Møller, Karen Østergaard, Scott J. Sherman, Richard Roxburgh, Barry Snow, John T. Slevin, Franca Cambi, James F. Gusella, Richard H. Myers   +45 more
openalex   +1 more source